We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Subcutaneous Formulation of MabThera Gets EU Nod
Read MoreHide Full Article
Roche Holding AG (RHHBY - Free Report) announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The approved dose for this indication is 1600 mg.
The subcutaneous (SC) formulation of MabThera is intended to save time and ease treatment burden over the intravenous form.
The approval was based on positive results from the phase Ib study, SAWYER, which demonstrated comparable safety and efficacy of the two formulations, both in combination with chemotherapy.
We note that MabThera is approved for the treatment of several types of blood cancers – certain forms of non-Hodgkin lymphoma (NHL) and CLL.
In the U.S., Roche markets MabThera as Rituxan, in collaboration with Biogen (BIIB - Free Report) .
Approval of the SC formulation of MabThera will broaden Roche’s hematology portfolio, which currently comprises approved drugs like MabThera/Rituxan, Gazyva/Gazyvaro, Tecentriq (atezolizumab) and Venclexta, and has an encouraging pipeline including investigational candidates like polatuzumab vedotin/RG7596 and a small-molecule antagonist of MDM2 (idasanutlin/RG7388).
Last month, the FDA granted accelerated approval to Tecentriq for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma, who experienced disease progression during or after platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
Moreover, Roche is developing emicizumab (ACE910) for the treatment of hemophilia A.
We expect investors to focus on new drug approvals at Roche, as the company’s top line could be marred by the entry of biosimilars for its key drugs (expected in the second half of 2017 in Europe) like MabThera and Herceptin.
Roche currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Pfizer Inc. (PFE - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Roche's Subcutaneous Formulation of MabThera Gets EU Nod
Roche Holding AG (RHHBY - Free Report) announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The approved dose for this indication is 1600 mg.
The subcutaneous (SC) formulation of MabThera is intended to save time and ease treatment burden over the intravenous form.
The approval was based on positive results from the phase Ib study, SAWYER, which demonstrated comparable safety and efficacy of the two formulations, both in combination with chemotherapy.
We note that MabThera is approved for the treatment of several types of blood cancers – certain forms of non-Hodgkin lymphoma (NHL) and CLL.
In the U.S., Roche markets MabThera as Rituxan, in collaboration with Biogen (BIIB - Free Report) .
Approval of the SC formulation of MabThera will broaden Roche’s hematology portfolio, which currently comprises approved drugs like MabThera/Rituxan, Gazyva/Gazyvaro, Tecentriq (atezolizumab) and Venclexta, and has an encouraging pipeline including investigational candidates like polatuzumab vedotin/RG7596 and a small-molecule antagonist of MDM2 (idasanutlin/RG7388).
Last month, the FDA granted accelerated approval to Tecentriq for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma, who experienced disease progression during or after platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.
Moreover, Roche is developing emicizumab (ACE910) for the treatment of hemophilia A.
We expect investors to focus on new drug approvals at Roche, as the company’s top line could be marred by the entry of biosimilars for its key drugs (expected in the second half of 2017 in Europe) like MabThera and Herceptin.
Roche currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Pfizer Inc. (PFE - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>